Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HIV vaccines. Back to primary school.

× No keyword cloud information.

18 in total

1. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors: Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal: J Virol Date: 2002-06 Impact factor: 5.103

2. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.

Authors: H X Liao; B Etemad-Moghadam; D C Montefiori; Y Sun; J Sodroski; R M Scearce; R W Doms; J R Thomasch; S Robinson; N L Letvin; B F Haynes
Journal: J Virol Date: 2000-01 Impact factor: 5.103

3. HCV entry and neutralizing antibodies: lessons from viral variants.

Authors: Mirjam B Zeisel; Thomas F Baumert
Journal: Future Microbiol Date: 2009-06 Impact factor: 3.165

4. The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion.

Authors: J D Reeves; T F Schulz
Journal: J Virol Date: 1997-02 Impact factor: 5.103

5. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.

Authors: T D Lockey; K S Slobod; T E Caver; S D'Costa; R J Owens; H M McClure; R W Compans; J L Hurwitz
Journal: Immunol Res Date: 2000 Impact factor: 2.829

6. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization.

Authors: F Gao; S G Morrison; D L Robertson; C L Thornton; S Craig; G Karlsson; J Sodroski; M Morgado; B Galvao-Castro; H von Briesen; S Beddows; J Weber; P M Sharp; G M Shaw; B H Hahn
Journal: J Virol Date: 1996-03 Impact factor: 5.103

7. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.

Authors: M R Boyd; K R Gustafson; J B McMahon; R H Shoemaker; B R O'Keefe; T Mori; R J Gulakowski; L Wu; M I Rivera; C M Laurencot; M J Currens; J H Cardellina; R W Buckheit; P L Nara; L K Pannell; R C Sowder; L E Henderson
Journal: Antimicrob Agents Chemother Date: 1997-07 Impact factor: 5.191

8. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.

Authors: M T Esser; T Mori; I Mondor; Q J Sattentau; B Dey; E A Berger; M R Boyd; J D Lifson
Journal: J Virol Date: 1999-05 Impact factor: 5.103

9. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules.

Authors: M C Gauduin; G P Allaway; P J Maddon; C F Barbas; D R Burton; R A Koup
Journal: J Virol Date: 1996-04 Impact factor: 5.103

10. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement.

Authors: L G Kostrikis; Y Cao; H Ngai; J P Moore; D D Ho
Journal: J Virol Date: 1996-01 Impact factor: 5.103